Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis.
To identify the major factors predicting the response to Methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients, we evaluated the relationship between the response to MTX and factors such as the concentration of MTX-polyglutamates (MTX-PGs) in erythrocytes (RBCs), genotypes of thymidylate synthase (TYMS) 5'-UTR (2R/3R) and 3'-UTR (-6/+6), 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, and other patient-related factors. Thirty-six Japanese RA patients were enrolled in this cohort study. The concentrations of MTX-PGs in RBCs were measured, and polymorphisms were determined using PCR-RFLP method. As an indicator of the accumulated capacity of MTX-PGs in the RBCs of each patient, the MTX dose/MTX-PGs (AC-MPG, l/week) was calculated. The response to MTX therapy was assessed using the MTX dose for a>or=50% decrease in CRP level (MTX dose for 50%CRP, mg/week), and the relationships between MTX dose for 50%CRP and various other factors were evaluated using multiple linear regression analysis. The MTX dose was 6.9+/-0.3 mg/week and the MTX-PGs concentration in RBCs was 97.3+/-8.1 nmol/l (n=36, blood samples=95, mean+/-S.D.). The range of MTX dose for 50%CRP was 2.0-13.0 mg/week. Most individual AC-MPG levels showed no change during the evaluation period (coefficient of variation=5.9%). Based on the results of multiple linear regression analysis, AC-MPG, TYMS 3'-UTR (-6/+6), and ESR at the start of MTX therapy were associated with the MTX dose for 50%CRP. AC-MPG, TYMS 3'-UTR (-6/+6), and ESR might be the major predictive factors for the response to MTX therapy in Japanese RA patients.
Inoue
Sachie
S
Division for Evaluation and Analysis of Drug Information, Keio University Faculty of Pharmacy, Tokyo, Japan.
Hashiguchi
Masayuki
M
Takagi
Kenji
K
Kawai
Shinichi
S
Mochizuki
Mayumi
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D044466:Asian People; D015331:Cohort Studies; D004912:Erythrocytes / Q000378:metabolism*; D005260:Female; D005544:Forecasting; D005838:Genotype; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood; D008875:Middle Aged; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000097:blood; D011110:Polymorphism, Genetic; D013763:Tetrahydrofolates / Q000235:genetics*; D013940:Thymidylate Synthase / Q000235:genetics*
D018501:Antirheumatic Agents; D013763:Tetrahydrofolates; C013123:5,10-methylenetetrahydrofolic acid; D011099:Polyglutamic Acid; C014085:methotrexate polyglutamate; D013940:Thymidylate Synthase; D008727:Methotrexate